About Iktos

Iktos utilizes generative AI and automated synthesis to streamline drug discovery, significantly reducing the time to identify viable drug candidates to under two years. By integrating AI-driven design, retrosynthesis, and robotics, the platform addresses the inefficiencies in traditional drug development processes, enhancing the speed and success rate of new treatment development.

```xml <problem> Traditional drug discovery processes are inefficient and time-consuming, often taking many years to identify viable drug candidates. These inefficiencies stem from the iterative nature of design, synthesis, testing, and analysis (DMTA) cycles, which require significant manual effort and resources. </problem> <solution> Iktos offers an AI-driven drug discovery platform that streamlines the DMTA cycle, significantly reducing the time and cost associated with identifying promising drug candidates. The platform integrates generative AI for molecular design (Makya), AI-driven retrosynthesis (Spaya), and automated synthesis through robotics, creating a closed-loop system for rapid iteration and optimization. By combining these technologies, Iktos accelerates the development of new treatments, enabling researchers to explore a wider chemical space and identify compounds with improved properties. The platform facilitates a more efficient and data-driven approach to drug discovery, ultimately leading to faster development timelines and increased success rates. </solution> <features> - **Makya:** Generative AI SaaS platform for de novo drug design, focusing on synthetic accessibility and multi-parametric optimization, including 3D constraints. - **Spaya:** AI-driven retrosynthesis platform that identifies feasible synthetic routes from target compounds to commercially available starting materials. - **Iktos Robotics:** Autonomous lab for automated compound synthesis and analysis, with ongoing integration of purification and biological testing. - High-throughput data generation and iterative optimization through a closed-loop DMTA process. - Customizable synthesis steps and constraints within the retrosynthesis platform. - Integration with various data providers to enhance the retrosynthesis process. </features> <target_audience> Iktos primarily targets pharmaceutical and biotech companies, as well as academic institutions, seeking to accelerate their drug discovery programs and improve the efficiency of their research and development efforts. </target_audience> <revenue_model> Iktos generates revenue through integrated drug discovery collaborations, licensing fees for its AI-driven software platforms (Makya and Spaya), and service fees for access to its autonomous robotic synthesis lab. </revenue_model> ```

What does Iktos do?

Where is Iktos located?

Iktos is based in Paris, France.

When was Iktos founded?

Iktos was founded in 2016.

How much funding has Iktos raised?

Iktos has raised 21040000.

Location

Paris, France

Founded

2016

Funding

21040000

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Iktos

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

iktos.ai LinkedIn Profile

Founded 2016 – Paris, France

Funding

Estimated Funding

$20M+

Team

No team information available.

Company Description

Problem

Traditional drug discovery processes are inefficient and time-consuming, often taking many years to identify viable drug candidates. These inefficiencies stem from the iterative nature of design, synthesis, testing, and analysis (DMTA) cycles, which require significant manual effort and resources.

Solution

Iktos offers an AI-driven drug discovery platform that streamlines the DMTA cycle, significantly reducing the time and cost associated with identifying promising drug candidates. The platform integrates generative AI for molecular design (Makya), AI-driven retrosynthesis (Spaya), and automated synthesis through robotics, creating a closed-loop system for rapid iteration and optimization. By combining these technologies, Iktos accelerates the development of new treatments, enabling researchers to explore a wider chemical space and identify compounds with improved properties. The platform facilitates a more efficient and data-driven approach to drug discovery, ultimately leading to faster development timelines and increased success rates.

Features

Makya: Generative AI SaaS platform for de novo drug design, focusing on synthetic accessibility and multi-parametric optimization, including 3D constraints.

Spaya: AI-driven retrosynthesis platform that identifies feasible synthetic routes from target compounds to commercially available starting materials.

Iktos Robotics: Autonomous lab for automated compound synthesis and analysis, with ongoing integration of purification and biological testing.

High-throughput data generation and iterative optimization through a closed-loop DMTA process.

Customizable synthesis steps and constraints within the retrosynthesis platform.

Integration with various data providers to enhance the retrosynthesis process.

Target Audience

Iktos primarily targets pharmaceutical and biotech companies, as well as academic institutions, seeking to accelerate their drug discovery programs and improve the efficiency of their research and development efforts.

Revenue Model

Iktos generates revenue through integrated drug discovery collaborations, licensing fees for its AI-driven software platforms (Makya and Spaya), and service fees for access to its autonomous robotic synthesis lab.